Beyond Medicine Unveils 'Clickless' TMJ DTx in U.S. at CES 2026

Beyond Medicine, a company specializing in digital therapeutics for temporomandibular joint disorder (TMD) improvement, is making its first foray into the U.S. market with its innovative digital therapeutic device, 'Clickless'. Beyond Medicine will participate in 'CES 2026', held in Las Vegas from January 6th to 9th next year, to showcase its differentiated clinical data-driven solution on the global stage. 'Clickless' is a smartphone-based, non-pharmacological digital therapeutic solution that focuses on correcting the fundamental behavioral and psychological causes of TMD, such as stress or teeth clenching. To overcome the limitations of existing physical therapy or drug prescriptions, which often fail to address behavioral factors and thus show high recurrence rates, it fundamentally applies cognitive behavioral therapy (CBT) techniques. This 6-week treatment program includes multifaceted functions such as ▲CBT-based behavior correction ▲meditation-based relaxation therapy ▲jaw muscle rehabilitation exercises ▲data-based treatment monitoring. Patients can analyze their facial movements and correct their daily habits using their smartphone cameras, while medical professionals can monitor patient data in real-time through a dashboard to establish optimized, personalized treatment plans. 'Clickless' has already demonstrated an excellent treatment effect of over 96% in a confirmatory clinical trial conducted at Hallym University Medical Center, and has been officially recognized for its technological prowess and efficacy by being designated as an innovative medical device by the Ministry of Food and Drug Safety (MFDS) for the first time in the dental field. Beyond Medicine recently attracted strategic investment from Samsung Fire & Marine Insurance and has been recognized for its high technological capabilities both domestically and internationally, being selected for the Ministry of SMEs and Startups' TIPS (Tech Incubator Program for Startup) R&D program and the Startup Jump-up Package (Deep Tech sector). Taking this CES participation as an opportunity, Beyond Medicine plans to actively pursue partnerships with leading university hospitals, distributors, and healthcare companies within the United States. The company aims to apply for the U.S. Food and Drug Administration's (FDA) 'Breakthrough Device Designation' in 2026, and is currently in the process of clinical suitability review, technical documentation, and quality standard enhancement. Furthermore, through the TIPS program, it is accelerating the development of an AI-based precise analysis and personalized treatment engine, securing future growth drivers. Kim Dae-hyun, CEO of Beyond Medicine, stated, "'CES 2026 will be the debut stage for 'Clickless' in the U.S. market and a critical turning point to strengthen our global competitiveness.' He added, 'Based on verified clinical data and unique technological prowess, we aim to challenge for an initial public offering (IPO) within four years and lead the global digital therapeutics market.'"